Abstract
Prion infections of the central nervous system (CNS) are characterized by a reactive gliosis and the subsequent degeneration of neuronal tissue. The activation of glial cells, which precedes neuronal death, is likely to be initially caused by the deposition of misfolded, in part proteinase K-resistant, isoforms (termed PrPTSE) of the normal cellular prion protein (PrPc) in the brain. Proinflammatory cytokines and chemokines released by PrPTSE-activated glial cells and stressed neurons may contribute directly or indirectly to the disease development by enhancement and generalization of the gliosis and via cytotoxicity for neurons. Recent studies have illustrated that interfering with inflammatory responses may represent a therapeutic approach to slow down the course of disease development. Hence, a better understanding of driving factors in neuroinflammation may well contribute to the development of improved strategies for treatment of prion diseases.
CNS & Neurological Disorders - Drug Targets
Title: Neuroinflammation in Prion Diseases: Concepts and Targets for Therapeutic Intervention
Volume: 8 Issue: 5
Author(s): Constanze Riemer, Sandra Gultner, Ines Heise, Nikola Holtkamp and Michael Baier
Affiliation:
Abstract: Prion infections of the central nervous system (CNS) are characterized by a reactive gliosis and the subsequent degeneration of neuronal tissue. The activation of glial cells, which precedes neuronal death, is likely to be initially caused by the deposition of misfolded, in part proteinase K-resistant, isoforms (termed PrPTSE) of the normal cellular prion protein (PrPc) in the brain. Proinflammatory cytokines and chemokines released by PrPTSE-activated glial cells and stressed neurons may contribute directly or indirectly to the disease development by enhancement and generalization of the gliosis and via cytotoxicity for neurons. Recent studies have illustrated that interfering with inflammatory responses may represent a therapeutic approach to slow down the course of disease development. Hence, a better understanding of driving factors in neuroinflammation may well contribute to the development of improved strategies for treatment of prion diseases.
Export Options
About this article
Cite this article as:
Riemer Constanze, Gultner Sandra, Heise Ines, Holtkamp Nikola and Baier Michael, Neuroinflammation in Prion Diseases: Concepts and Targets for Therapeutic Intervention, CNS & Neurological Disorders - Drug Targets 2009; 8 (5) . https://dx.doi.org/10.2174/187152709789542014
DOI https://dx.doi.org/10.2174/187152709789542014 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Novel Piperazinyl Derivatives with Anti-Hyperalgesic, Anti-Allodynic and Anti-Inflammatory activities Useful for the Treatment of Neuropathic Pain
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Chelating Agents for Metal Intoxication
Current Medicinal Chemistry Neuroprotection and Hypothermia in Infants and Children
Current Drug Targets Antibody Fragments as Potential Biopharmaceuticals for Cancer Therapy: Success and Limitations
Current Medicinal Chemistry Hepatic Encephalopathy: Cause and Possible Management with Botanicals
Recent Patents on Inflammation & Allergy Drug Discovery The Use of Ghrelin and Ghrelin Receptor Agonists as a Treatment for Animal Models of Disease: Efficacy and Mechanism
Current Pharmaceutical Design Aging Blunts Ischemic-Preconditioning-Induced Neuroprotection Following Transient Global Ischemia in Rats
Current Neurovascular Research Transgenic Mouse Models of Tauopathy in Drug Discovery
CNS & Neurological Disorders - Drug Targets Use of Hemoglobin for Delivering Exogenous Carbon Monoxide in Medicinal Applications
Current Medicinal Chemistry Anomalies of Self in First-Episode Psychosis
Current Psychiatry Reviews Therapeutic Proteins: A to Z
Protein & Peptide Letters Leptin and Interleukin-1β Modulate Neuronal Glutamate Release and Protect Against Glucose-Oxygen-Serum Deprivation
Current Neurovascular Research Triptolide Rescues Spatial Memory Deficits and Amyloid-β Aggregation Accompanied by Inhibition of Inflammatory Responses and MAPKs Activity in APP/PS1 Transgenic Mice
Current Alzheimer Research Effects of Novel Monoamine Oxidases and Cholinesterases Targeting Compounds on Brain Neurotransmitters and Behavior in Rat Model of Vascular Dementia
Current Pharmaceutical Design Effects of Thyroid Hormones on Memory and on Na+, K+-ATPase Activity in Rat Brain
Current Neurovascular Research Effects of Subhypothermia on Ca2+, Mg2+, Excitatory Amino Acids and Plasma Endothelin in Brain Tissues of Mice with Acute Cerebral Infarction
Vascular Disease Prevention (Discontinued) Alkaloids Pharmacological Activities - Prospects for the Development of Phytopharmaceuticals for Neurodegenerative Diseases
Current Pharmaceutical Biotechnology Conference Report (8th Annual Meeting of the Society for the Study of Neuroprotection and Neuroplasticity)
CNS & Neurological Disorders - Drug Targets Advanced Approaches of Bioactive Peptide Molecules and Protein Drug Delivery Systems
Current Pharmaceutical Design Experimental Methods and Transport Models for Drug Delivery Across the Blood-Brain Barrier
Current Pharmaceutical Biotechnology